Fludrocortisone acetate
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1955
- First approval year
- 1955
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Fludrocortisone acetate
- Molecular weight
- 422.49
- Structure (SMILES)
- CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
- astonin
- Astonin
- florinef
- Florinef
- fludrocortisone acetate
- Fludrocortisone acetate
- fludrocortone
- Fludrocortone
- panotile
- Panotile
- fludrocortisona
- Fludrocortisona
- fludrocortisone 21 acetate
- fludrocortisone 21 acetate mi
- Fludrocortisone 21-acetate
- FLUDROCORTISONE 21-ACETATE [MI]
- fludrocortisone acetate
- Fludrocortisone acetate
- FLUDROCORTISONE ACETATE [EP MONOGRAPH]
- FLUDROCORTISONE ACETATE [JAN]
- FLUDROCORTISONE ACETATE [MART.]
- FLUDROCORTISONE ACETATE [ORANGE BOOK]
- FLUDROCORTISONE ACETATE [USP MONOGRAPH]
- FLUDROCORTISONE ACETATE [USP-RS]
- FLUDROCORTISONE ACETATE [VANDF]
- Fludrocortisone acetate [WHO-DD]
- FLUDROCORTISONE ACETATE [WHO-IP]
- fludrocortisone acetate ep monograph
- fludrocortisone acetate jan
- fludrocortisone acetate mart
- fludrocortisone acetate orange book
- fludrocortisone acetate usp monograph
- fludrocortisone acetate usp rs
- fludrocortisone acetate vandf
- fludrocortisone acetate who dd
And 11 more, listed on the interactive page.
- ATC classification codes
- H02AA02
Sources for recorded values
- CAS registry numbers
- 514-36-3
- ChEMBL ID
- CHEMBL1201010
- InChIKey
- SYWHXTATXSMDSB-GSLJADNHSA-N
- PubChem compound IDs
- 225609
- RxNorm IDs (RxCUI)
- 165516
- FDA ingredient codes (UNII)
- V47IF0PVH4
- Applicant
- CASPER PHARMA LLC
- Approval date
- 18 Aug 1955
- Application number
- NDA010060
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- fludrocortisone
- Type
- Synthetic organic
- Drug name stem
- -cort-
Administration routes
- Oral
Mechanisms of action
- Mechanism
- Mineralocorticoid receptor agonist
- Action type
- Agonist
- Target
- Mineralocorticoid receptor
- Protein identifier
- P08235
Open Targets mechanisms
- Mechanism
- Mineralocorticoid receptor agonist
- Action type
- Agonist
- Target
- Mineralocorticoid receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- NR3C2
- Protein identifier
- P08235
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Subarachnoid Hemorrhage
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000713
- Subject identifier
- D013345
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- Shock, Septic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006834
- Subject identifier
- D012772
- Condition
- Hearing Loss, Sensorineural
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:1001176
- Subject identifier
- D006319
- Condition
- Depressive Disorder
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Parkinson Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Ovarian Hyperstimulation Syndrome
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0011972
- Subject identifier
- D016471
- Condition
- Addison Disease
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0015128
- Subject identifier
- D000224
- Condition
- Addison Disease
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0015129
- Subject identifier
- D000224
- Condition
- Adrenogenital Syndrome
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0015898
- Subject identifier
- D047808
- Condition
- Adrenal Hyperplasia, Congenital
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0018479
- Subject identifier
- D000312
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000673
- Condition identifier
- EFO_0000694
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000713
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001176
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005469
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0015128
- Condition identifier
- MONDO_0015128
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0015129
- Condition identifier
- MONDO_0015129
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0015898
- Condition identifier
- MONDO_0015898
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0018479
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018479
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0043373
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- Event
- accelerated hypertension
- Reports
- 3
- Reporting signal score
- 12.8505
- Event
- acute psychosis
- Reports
- 11
- Reporting signal score
- 41.1174
- Event
- adrenal insufficiency
- Reports
- 8
- Reporting signal score
- 17.5655
- Event
- adrenocortical insufficiency acute
- Reports
- 11
- Reporting signal score
- 48.8213
- Event
- androgen deficiency
- Reports
- 3
- Reporting signal score
- 14.6357
- Event
- asthenia
- Reports
- 21
- Reporting signal score
- 7.56381
- Event
- autonomic failure syndrome
- Reports
- 2
- Reporting signal score
- 12.5619
- Event
- blood pressure increased
- Reports
- 12
- Reporting signal score
- 8.60557
- Event
- cerebral hypoperfusion
- Reports
- 4
- Reporting signal score
- 18.85
- Event
- cerebrovascular accident
- Reports
- 50
- Reporting signal score
- 88.5132
- Event
- cognitive disorder
- Reports
- 11
- Reporting signal score
- 15.9003
- Event
- confusional state
- Reports
- 22
- Reporting signal score
- 20.4421
- Event
- dehydration
- Reports
- 7
- Reporting signal score
- 6.65963
- Event
- dermatitis bullous
- Reports
- 7
- Reporting signal score
- 15.5324
- Event
- disorientation
- Reports
- 16
- Reporting signal score
- 28.3701
- Event
- dizziness
- Reports
- 31
- Reporting signal score
- 13.2928
- Event
- dizziness postural
- Reports
- 4
- Reporting signal score
- 8.406
- Event
- dyskinesia
- Reports
- 11
- Reporting signal score
- 17.673
- Event
- dystonia
- Reports
- 13
- Reporting signal score
- 30.491
- Event
- electrocardiogram qrs complex prolonged
- Reports
- 4
- Reporting signal score
- 8.71816
- Event
- eosinophilic oesophagitis
- Reports
- 7
- Reporting signal score
- 34.4379
- Event
- executive dysfunction
- Reports
- 3
- Reporting signal score
- 13.601
- Event
- fall
- Reports
- 26
- Reporting signal score
- 13.8349
- Event
- foaming at mouth
- Reports
- 3
- Reporting signal score
- 9.94516
- Event
- glomerulonephritis membranous
- Reports
- 5
- Reporting signal score
- 18.5812
And 30 more, listed on the interactive page.
- NCT00320099
- NCT00625209
- NCT02069288
- NCT04494789
- NCT05001854
- NCT00623766
- NCT01186185
- NCT01648998
- NCT01993680
- NCT03548246
- NCT04351126
- NCT05453214
- NCT06104449
- NCT06136598
- NCT06136650
- NCT06353386
- NCT06136624
- NCT06409364
- Dose
- 0.1 mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Patient response influences dosage
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 100.9
- Calculated partition coefficient (ALogP)
- 2.44
- Calculated partition coefficient (XLogP)
- 1.7
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 30
- Molecular formula
- C23H31FO6
- Monoisotopic mass
- 422.21046687
- Natural product
- No
- 0115-7033
- 0615-6562
- 0904-7317
- 42291-764
- 50268-330
- 51407-705
- 68084-288
- 70954-252
- 71930-088
- 72578-164
- 72603-170
- 55154-2644
- 55154-6645
- 69238-7033
- 70771-1893
- 71335-2454
- Recorded assays
- 747
- Active assays
- 5
- Confirmatory
- Other
- Anti-Inflammatory Agents
Related records
Trials (14)
- A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
- A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
- A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
- A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
- Clinical Trial for the Prevention of Vasovagal Syncope
- Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS
- Midodrine and Fludrocortisone for Vasovagal Syncope
- Mineralocorticoid Use in COVID-19 Patients
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Approved for (3)
- Adrenogenital syndrome
- Chronic primary adrenal insufficiency
- Primary adrenal insufficiency
In development for (12)
- Congenital adrenal hyperplasia Phase 2
- COVID-19 Phase 3
- Depressive disorder Phase 1
- Melanoma Phase 2
- Metastatic prostate carcinoma Phase 3
- Ovarian hyperstimulation syndrome Phase 2
- Parkinson disease Phase 2
- Prostate adenocarcinoma Phase 3
- Sensorineural hearing loss disorder Early phase 1
- Severe acute respiratory syndrome Phase 3
- Subarachnoid hemorrhage Phase 2
- Toxic shock syndrome Phase 3
Targets (1)
- NR3C2 Mineralocorticoid receptor agonist